ENYO Pharma Secures $6M Series C Funding to Advance Revolutionary Kidney and Liver Therapeutics

ENYO Pharma, a pioneering biopharmaceutical company focused on creating innovative therapeutics with fibrolytic and anti-inflammatory properties, is proud to announce the successful raising of $6,000,000 in funding.

This exciting capital infusion is a resounding endorsement of our mission to tackle diseases associated with impaired kidney function while also extending our impact on liver-related conditions.

The newly secured funds will be instrumental in advancing our current clinical pipeline and further propelling our research initiatives into novel treatment avenues.

At the forefront of our efforts is the ongoing Phase 2 trial of our lead compound, Vonafexor, which is being evaluated in the context of Chronic Kidney Diseases (CKD) and rare kidney disorders such as Alport syndrome.

Vonafexor’s potential is not limited to kidney ailments, however, as our research also targets liver diseases, including Non-Alcoholic SteatoHepatitis (NASH), and extends to addressing infectious liver diseases such as chronic Hepatitis B and Hepatitis D.

With this financial backing, ENYO Pharma is poised to not only accelerate the progression of clinical trials but also to invest in critical research infrastructure that will enable us to explore the therapeutic benefits of Vonafexor across multiple indications.

This development marks a significant milestone for our company and reinforces our commitment to developing breakthrough therapies that promise to improve patient outcomes and quality of life.

As we move forward, we remain dedicated to transparency, scientific rigor, and innovation, continually striving to deliver transformative solutions for patients suffering from some of the most challenging kidney and liver diseases today.